A Long-Term, Phase 2, Multicenter, Randomized, Open-Label Comparative Safety Study of LY2140023 Versus Atypical Antipsychotic Standard of Care in Patients With DSM-IV-TR Schizophrenia.

Trial Profile

A Long-Term, Phase 2, Multicenter, Randomized, Open-Label Comparative Safety Study of LY2140023 Versus Atypical Antipsychotic Standard of Care in Patients With DSM-IV-TR Schizophrenia.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2013

At a glance

  • Drugs Pomaglumetad methionil (Primary) ; Aripiprazole; Olanzapine; Risperidone
  • Indications Schizophrenia
  • Focus Adverse reactions; Biomarker; Pharmacogenomic
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Feb 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top